Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
Can you paint the profile of the post-ACS patient with T2D in whom the aggregate CV risk exceeds a threshold that supports a strategy of PCSK9-mediated LDL-C reduction in order to achieve levels of less than 70 mg/dL; or, even less than 50 mg/dL?
Presenter
Professor of Endocrinology and Metabolism School of Medicine, University of Pisa Chief of the Section of Diabetes University of Pisa, Italy Clinical Associate Professor of Medicine University of Texas, San Antonio Health Science Center San Antonio, Texas